Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010--11. MMWR 2010; 59 (31): 989-992.

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices.
• Description:
  During the 2010 influenza season in Australia, administration of a 2010 Southern Hemisphere seasonal influenza trivalent inactivated vaccine (TIV) (Fluvax Junior and Fluvax) manufactured by CSL Biotherapies was associated with increased frequency of fever and febrile seizures in children aged 6 months through 4 years. Postmarketing surveillance indicated increased reports of fever in children aged 5-8 years after vaccination with Fluvax compared to previous seasons. An antigenically equivalent 2010-11 Northern Hemisphere seasonal influenza TIV (Afluria) manufactured by CSL Biotherapies is approved by the Food and Drug Administration (FDA) for persons aged >or=6 months in the United States. Prescribing information for the 2010-11 Afluria formulation includes a warning that "Administration of CSL's Southern Hemisphere influenza vaccine has been associated with increased postmarketing reports of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years". In the United States, annual influenza vaccination is recommended for all persons aged >or=6 months. On August 5, 2010, the Advisory Committee on Immunization Practices (ACIP) recommended that the 2010-11 Afluria vaccine not be administered to children aged 6 months through 8 years. Other age-appropriate, licensed seasonal influenza vaccine formulations should be used for prevention of influenza in these children. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5-8 years who has a medical condition that increases their risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of Afluria use before administering this vaccine to children aged 5-8 years.
• Subjects:
  Child Child, Preschool Fever Humans Infant Influenza, Human Influenza Vaccines Product Surveillance, Postmarketing Risk Factors Seizures, Febrile
• Source:
  MMWR. Morbidity and mortality weekly report. 2010; 59(31):989-92.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  20703207
• Document Type:
  Journal Article
• Place as Subject:
  Australia ; New Zealand ; United States
• Pages in Document:
  4 pdf pages
• Volume:
  59
• Issue:
  31
• Collection(s):
  Guidelines and Recommendations Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:e8b8df5b839babeddd6d89dc567b67a75d9e15de4ac994d02fa4f639e2aa78bcdc9338efe6324ef3139d70f2f02b7f4da41414b5b446d0a283200d6bad783641
• Download URL:
  https://stacks.cdc.gov/view/cdc/7452/cdc_7452_DS1.pdf
• File Type:
  [PDF - 305.76 KB ]